FDA analysis indicates second J&J shot provides greater immunity than first

Food and Drug Administration staff provided their analysis of Johnson & Johnson’s COVID-19 booster application today, indicating that a second dose provides substantially more protection against SARS-CoV-2 than the initial shot. The analysis is among a trove of data that will be considered this week by the agency’s Vaccines and Related Biological Products Advisory Committee. According to FDA’s analysis, a second, booster dose of the J&J vaccine yielded a 94% efficacy against moderate-to-severe COVID-19; data indicates that the first dose’s efficacy is 70%.
Related News Articles
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…